21st Austria weekly - Marinomed, Frequentis (17/12/2024)

Marinomed: Marinomed Biotech AG announced that all necessary conditions for the completion of the ongoing restructuring proceedings without self-administration have been met. The funds for the cash quota and for the costs of the proceedings have been deposited with the insolvency administrator. Within the next two weeks, the creditors' cash quotas will be paid out from these funds. In addition, a standstill agreement has been concluded with the EIB for the payment of the cash quota until the end of April 2025. The standstill was necessary because Marinomed will only receive the first partial payment from the sale of the Carragelose business after the closing. This can take up to three months. All requirements have thus been met to end the restructuring proceedings and the administration by the insolvency administrator.
Marinomed Biotech: weekly performance: -5.45%

Frequentis: Frequentis has been selected by Avinor AS, the state-owned operator of Norway’s airports and air navigation services, to modernise air traffic management at Oslo Airport, Norway’s largest, as well as up to 14 regional airports. The New Tower System Oslo (NeTSO) project will introduce state-of-the-art technology to enhance safety and efficiency, while preparing for future growth and ensuring European Common Project One compliance.
Frequentis: weekly performance: -3.20%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (17/12/2024)

Christian Drastil: Wiener Börse Plausch

SportWoche Podcast #140: Flag Football und Österreichs Top-Position dabei, erklärt von Ines-Jeanne Paupie

Bildnachweis

1. Frequentis AG: Andreas Gerstinger erhält International Safety Award; Dave West (President ISSS), Andreas Gerstinger, Michael McKelvey (Executive VP ISSS), © Frequentis , (© Aussendung)   >> Öffnen auf photaq.com

Aktien auf dem Radar:Pierer Mobility, UBM, Palfinger, Immofinanz, Addiko Bank, CA Immo, SBO, Porr, Rosenbauer, EuroTeleSites AG, Frequentis, Kostad, Linz Textil Holding, Marinomed Biotech, Wiener Privatbank, Warimpex, Agrana, Amag, EVN, Flughafen Wien, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG, E.ON , BASF, Zalando, Mercedes-Benz Group, Allianz, Hannover Rück.

Random Partner

---

Marinomed
Erforscht und entwickelt völlig neuartige Technologieplattformen, die innovative Therapien gegen Atemwegs- und Augenerkrankungen ermöglichen. Aus wissenschaftlichen Ideen werden so neue Patente, Marken und Produkte geschaffen.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner